Organophosphate Poisoning. Its ED management, complications, difficulties faced in Ed for managing OP and it's solutions, long term sequel of OP. Recent advances in OP management. And 5-10 super difficult and tricky questions regarding OP poisoning which can be asked as examiner to MD Emergency medicine resident in exams.

Reading File

Finding Sources

Searching PubMed

"organophosphate poisoning" AND management

Searching the Web

organophosphate poisoning ED management recent advances 2024 2025

Reading File

Reading Article

PMID: 42258859

Reading Article

PMID: 38797902

Finding Sources

Reading File

Finding Sources

Reading File

Organophosphate (OP) Poisoning - Comprehensive ED Reference

PATHOPHYSIOLOGY (Quick Recall)

Organophosphates irreversibly inhibit acetylcholinesterase (AChE) and pseudocholinesterase (BuChE), causing acetylcholine (ACh) accumulation at:

Muscarinic sites - postganglionic parasympathetic (glands, smooth muscle, heart)
Nicotinic sites - NMJ (skeletal muscle) and autonomic ganglia
CNS - NMDA receptor involvement + ACh accumulation - seizures, coma

Aging: The irreversible conformational change locking OP permanently to AChE. Once aged, oximes cannot regenerate the enzyme. Time to aging varies: soman ages in minutes; parathion/malathion may take hours to days. This is why oximes must be given EARLY.

CLINICAL FEATURES

SLUDGE / DUMBELS Mnemonics

SLUDGE	DUMBELS
Salivation	Defecation
Lacrimation	Urination
Urination	Miosis
Defecation	Bradycardia / Bronchospasm / Bronchorrhea
GI distress	Emesis
Emesis	Lacrimation
	Seizures / Salivation

Muscarinic effects: miosis (most sensitive sign), bradycardia, bronchospasm, bronchorrhea, salivation, lacrimation, urination, defecation, abdominal cramps, pulmonary edema

Nicotinic effects (MTWHF - Monday Through Wednesday Have Fun): Mydriasis (can override miosis!), Tachycardia, Weakness, Hypertension, Fasciculations

CNS effects: anxiety, seizures, coma, respiratory depression

Key trap: Tachycardia does NOT exclude OP poisoning - nicotinic stimulation can dominate the muscarinic bradycardia.

Pulmonary edema in OP must be distinguished from bronchorrhea/bronchospasm - it results from inflammatory mediator release and increased vascular permeability, and is NOT fluid overload - diuretics are NOT indicated. - Rosen's Emergency Medicine, 10e

ED MANAGEMENT

Step 1 - Decontamination (Self-Protection First)

PPE is mandatory before approaching the patient. Latex gloves are INSUFFICIENT - use nitrile or neoprene gloves. Healthcare workers have been poisoned by contaminated patients.
Remove all clothing (eliminates up to 80% of dermal exposure)
Copious water irrigation of skin and eyes
For ingestion: gastric lavage only if early presentation (<1 hour), airway is secured, and benefit outweighs risk. The 2026 umbrella review found gastric lavage has doubtful efficacy and may be harmful - do NOT routinely perform it.
Activated charcoal: no proven benefit and aspiration risk in the drowsy/seizing patient

Step 2 - Stabilization (ABCDEs)

Airway is the priority. Succinylcholine should be used CAUTIOUSLY for RSI - pseudocholinesterase (BuChE) is inhibited by OP, prolonging succinylcholine's duration of action dramatically (can persist 30-60+ minutes). Rocuronium (with sugammadex reversal available) is preferred.
Avoid benzodiazepines for intubation induction (seizure prophylaxis role, but not induction agent)
Secure IV access x2, cardiac monitor, pulse oximetry

Step 3 - Antidotes

A. ATROPINE - The Cornerstone

Mechanism: Competitive antagonist at muscarinic receptors. Does NOT reverse nicotinic effects (muscle weakness, fasciculations) or CNS effects.

Endpoint of atropinization: Drying of secretions (bronchorrhea/salivation), not heart rate or pupil size.

Do NOT use HR or pupil dilation as endpoint - nicotinic tachycardia and a mixed picture can confuse
Atropine is titrated to DRY LUNGS, NOT to a heart rate target

Dosing:

Initial: 2-4 mg IV in adults (some guidelines start at 2-5 mg; children: 0.02-0.05 mg/kg)
Double the dose every 3-5 minutes until secretions dry
Severe cases may require hundreds of milligrams over hours
Atropine infusion: start at 10-20% of loading dose per hour once secretions controlled
In mass casualty settings, sublingual atropine has been studied as an alternative route

Common error: Under-dosing atropine out of fear of causing "atropine toxicity." In OP poisoning, the ACh excess protects against atropine toxicity; patients can tolerate large doses.

B. PRALIDOXIME (2-PAM) / OXIMES

Mechanism: Reactivates phosphorylated AChE if given BEFORE aging occurs. Also has direct antimuscarinic and anti-nicotinic properties.

Indications for oxime use (Rosen's criteria):

Respiratory failure or depression
Muscle fasciculations
Seizures
Dysrhythmias
Hemodynamic instability
Large amounts or repeated doses of atropine needed

Dosing (pralidoxime):

Load: 1-2 g IV over 15-30 minutes (children: 25-50 mg/kg)
Infusion: 500 mg/hour (or 10-20 mg/kg/hr)

Controversy: The landmark Eddleston 2009 RCT (Lancet) and subsequent meta-analyses showed NO mortality benefit from pralidoxime. However, the 2026 umbrella review (Chauhan et al., West J Emerg Med 2026, PMID 42258859) concluded: "Atropine remains the mainstay. Oximes showed neither benefit nor harm - WHO still recommends their use as an adjuvant." Current practice: give atropine first; oximes as adjunct in severe cases.

C. BENZODIAZEPINES

Lorazepam or diazepam for seizures - first-line
Also reduce anxiety and muscle fasciculations
Phenytoin/phenobarbital are INEFFECTIVE for OP seizures (GABA-ergic mechanism, not sodium channel)
Propofol may be used for refractory seizures

D. GLYCOPYRROLATE (Emerging)

Quaternary ammonium - does NOT cross the blood-brain barrier (unlike atropine)
Useful for peripheral muscarinic control without worsening CNS confusion/agitation
2025 systematic review (Rashid et al., PMID 38797902): patients treated with glycopyrrolate had fewer hospitalization days and fewer adverse events, but evidence remains low quality - not yet standard of care

Step 4 - Monitoring and Investigations

Investigation	Purpose
RBC AChE (true cholinesterase)	Confirms OP exposure; correlates with severity; baseline for oxime response
Plasma BuChE (pseudocholinesterase)	More readily available; falls first; but less specific
ABG	Respiratory failure, type 2 resp failure common
ECG	QTc prolongation, bradycardia, VT, torsades
BMP/metabolic panel	Electrolytes, renal function
Chest X-ray	Aspiration, pulmonary edema
Blood glucose	Hyperglycemia from sympathetic activation
Urine organophosphate metabolites	Confirms exposure type (e.g., alkyl phosphates)

Critical note: Do NOT wait for cholinesterase levels to begin treatment in a symptomatic patient. Treat empirically. - Rosen's Emergency Medicine, 10e

COMPLICATIONS

Acute Complications

Complication	Mechanism	Management
Respiratory failure	Bronchospasm + bronchorrhea + NMJ paralysis of diaphragm + CNS depression	Aggressive atropine, early intubation
Status epilepticus	CNS ACh accumulation + NMDA activation	Benzodiazepines (first-line), NOT phenytoin
QTc prolongation / Torsades	Direct cardiotoxicity + electrolyte disturbance	Magnesium, correct electrolytes
Aspiration pneumonitis	Excessive secretions, depressed consciousness	Airway protection, antibiotics if pneumonia develops
Pulmonary edema	Non-cardiogenic, inflammatory	NOT diuretics; supportive
Rhabdomyolysis	Nicotinic hyperstimulation	IVF, monitor CK, urine output
Pancreatic injury	Direct toxicity	Monitor amylase/lipase

FOUR CLINICAL SYNDROMES OF OP POISONING

1. Acute Cholinergic Crisis

Onset: within minutes to 8 hours (nearly all within 24 hours)
Classic SLUDGE/DUMBELS as above
Most deaths in this phase from respiratory failure

2. Intermediate Syndrome (IMS)

Onset: 24-96 hours after acute cholinergic crisis (occasionally up to 4 days)
After apparent clinical recovery from the acute phase
Characterized by: proximal limb weakness, neck flexor weakness, cranial nerve palsies (especially facial), respiratory muscle weakness leading to respiratory failure
NOT due to nicotinic/muscarinic excess - mechanism uncertain, likely related to prolonged NMJ dysfunction
NOT prevented or reversed by atropine or oximes
Management: supportive, mechanical ventilation if needed
Duration: 2-3 weeks; usually fully reversible
Risk factor: high initial OP dose, delayed treatment

3. Organophosphate-Induced Delayed Neuropathy (OPIDN)

Onset: 1-3 weeks after acute poisoning
Peripheral neuropathy: symmetrical, predominantly motor > sensory
Distal limb weakness, ataxia, ascending pattern; can progress to paralysis
Respiratory muscles spared (distinguishes from acute poisoning)
Mechanism: inhibition of neuropathy target esterase (NTE), separate from AChE
No specific treatment; physiotherapy and supportive care
Partial or complete recovery may occur over months to years

4. Chronic OP-Induced Neuropsychiatric Disorder (COPIND)

Low-level chronic exposure (farmworkers, etc.)
Cognitive impairment, memory loss, depression, anxiety, psychosis
Parkinson's-like syndrome (tremor, rigidity)
May persist for years after cessation of exposure

DIFFICULTIES FACED IN ED - WITH SOLUTIONS

1. Massive Atropine Requirement

Problem: May need 100-1000 mg over hours; most EDs stock limited quantities
Solution: Early contact with pharmacy, poison control; have powdered atropine reconstitution protocol; coordinate with blood bank/pharmacy for emergency stock

2. Diagnostic Confusion - Atypical Presentations

Problem: Nicotinic features may dominate (tachycardia, hypertension, mydriasis) masking classic cholinergic picture; can mimic cardiac event, sepsis, or psychiatric emergency
Solution: Look for the combination + environmental/occupational history; low threshold for empiric atropine in suspected cases; check RBC/plasma cholinesterase

3. RSI Drug Choice

Problem: Succinylcholine contraindicated due to prolonged paralysis from BuChE inhibition
Solution: Rocuronium as default NMB for RSI in all suspected OP cases; have sugammadex available

4. Cholinesterase Levels Not Available in Real-Time

Problem: RBC AChE sent to reference labs; results not available for hours-days
Solution: Treat clinically based on toxidrome; use plasma BuChE if available as a proxy; serial monitoring once results available

5. Healthcare Worker Secondary Contamination

Problem: Providers develop symptoms from contact with OP-contaminated patients
Solution: STRICT PPE protocol; decontamination area outside main ED; nitrile/neoprene gloves mandatory; consider HAZMAT involvement

6. Seizures Refractory to Benzodiazepines

Problem: Status epilepticus may require escalating doses; phenytoin does NOT work
Solution: High-dose lorazepam/diazepam → propofol → barbiturate coma; do NOT waste time with phenytoin; ensure adequate atropinization concurrently

7. Ventilator Management in Intubated OP Patients

Problem: Excessive secretions block ETT; prolonged ventilation due to neuromuscular weakness (intermediate syndrome)
Solution: Frequent suctioning; atropine to dry secretions; expect ventilator weaning to be prolonged; early tracheostomy consideration in IMS

8. Delayed Intermediate Syndrome After Apparent Recovery

Problem: Patient "recovers" and is about to be discharged, then decompensates
Solution: Mandatory minimum 24-48 hour observation for ALL symptomatic OP poisonings; daily respiratory muscle assessment (negative inspiratory force, FVC); do NOT discharge until stable for 24 hours after stopping atropine

9. Differentiating OP from Carbamate Poisoning

Problem: Clinically identical, but carbamates do NOT cause aging and AChE spontaneously regenerates; oximes controversial (possibly harmful for some carbamates)
Solution: If cannot distinguish, treat as OP; give atropine definitively; use oximes only if severe or if OP vs carbamate distinction impossible

10. Psychiatric/Intentional Ingestions with Delayed Presentation

Problem: Lipid-soluble OPs (e.g., fenthion) absorbed into fat stores; initial mild symptoms followed by delayed massive release and toxicity
Solution: Extended observation (24-96 hours) for fat-soluble compounds; serial cholinesterase levels; do NOT discharge based on initial symptom resolution

LONG-TERM SEQUELAE

Sequela	Timeline	Features
Intermediate Syndrome	1-4 days post-acute	Proximal weakness, cranial nerve palsies, respiratory failure
OPIDN	1-3 weeks post-acute	Peripheral neuropathy, axonopathy, partial recovery
COPIND	Weeks-months-years	Neuropsychiatric: depression, anxiety, cognitive decline, psychosis
Parkinsonism	Months-years	Dopaminergic damage; especially with chronic low-level exposure
Chronic organophosphate-induced neuropsychiatric disorder	Long-term	Personality change, memory impairment, executive dysfunction
Recurrent seizures / Epilepsy	Post-acute	Hippocampal damage from status epilepticus
PTSD	Post-hospitalization	Especially in intentional ingestion cases
Cardiac sequelae	Post-acute	Prolonged QTc, arrhythmia risk; cardiotoxic cardiomyopathy rare

RECENT ADVANCES (2023-2026)

1. Oximes - The Great Controversy Settles

The 2026 umbrella review (Chauhan et al., West J Emerg Med, PMID 42258859) - the most comprehensive synthesis to date - found oximes show neither benefit nor harm. WHO still recommends use as adjuvant to atropine. Current consensus: don't withhold, but don't expect a mortality benefit.

2. Glycopyrrolate as Atropine Adjunct

2025 systematic review (Rashid et al., PMID 38797902): glycopyrrolate (which does not cross BBB) reduces hospitalization duration and adverse events. May reduce the CNS side effects (delirium, agitation) seen with large atropine doses. Not yet standard of care - awaiting larger RCTs.

3. Magnesium Sulfate

2024-2025 scoping review (Clin Exp Emerg Med 2025): Mg2+ acts as NMDA receptor antagonist and calcium channel blocker, potentially reducing seizures and cardiotoxicity. Some RCTs show mortality reduction, but evidence quality is low. Not yet recommended as routine adjunct (umbrella review 2026 advises against routine use).

4. Lipid Emulsion Therapy

Theoretical basis: lipid-soluble OPs could be sequestered in a "lipid sink." Small studies show possible benefit in severe cases. 2026 umbrella review: promising but evidence very low quality; NOT recommended routinely.

5. Plasma Exchange / Hemoperfusion

Some Asian RCTs show mortality benefit. 2026 umbrella review: evidence from very low-quality studies; NOT recommended as routine.

6. Biomarker-Guided Atropine Titration

Research into using end-tidal CO2 and point-of-care BuChE to guide atropine dosing in real-time - reduces both under-dosing and over-dosing.

7. Novel Antidotes in Research

Bioscavengers (e.g., recombinant BuChE): Pre-exposure prophylaxis (military context) that "mop up" OP before it reaches AChE
CNS-penetrant oximes: Current pralidoxime does not cross BBB well; newer obidoxime (Europe) and K203 (research) may have better CNS penetration
Neuroprotective strategies: Scopolamine, ketamine as NMDA antagonists to prevent seizure-related brain injury

8. High-Dose Insulin Euglycemic Therapy (HIET)

For refractory hemodynamic compromise in OP - emerging evidence in severe cases with cardiotoxicity.

10 SUPER-DIFFICULT EXAMINER QUESTIONS FOR MD EMERGENCY MEDICINE VIVA

Q1 - The Paradox of Miosis vs Mydriasis

"A farmer is brought in with suspected OP poisoning. His pupils are dilated (8mm bilaterally). The intern says it can't be OP because miosis is the classic sign. You disagree. Defend your position."

Model Answer: Miosis is the most sensitive muscarinic sign but is NOT invariable. Nicotinic effects at the iris dilator can OVERRIDE the muscarinic miosis, producing mydriasis, especially with compounds that have predominant nicotinic action or in combined adrenergic stimulation. Additionally, coingestants (e.g., sympathomimetics, alcohol) can dilate pupils. Ocular exposure causes miosis, but systemic exposure with predominant nicotinic stimulation can cause mydriasis. Pupil size should NEVER be used alone to rule in or rule out OP poisoning.

Q2 - The Atropinization Endpoint Trap

"You've given 20mg of atropine to your OP-poisoned patient. His heart rate is now 130 bpm and his pupils are dilated. A nurse says you've over-atropinized him and should stop. What is your response?"

Model Answer: The endpoint of atropinization is DRYING OF BRONCHIAL SECRETIONS - not heart rate, pupil size, or skin dryness. Tachycardia may represent nicotinic stimulation from the OP itself rather than atropine toxicity. Similarly, pupil dilation can occur due to nicotinic effect on the iris dilator. If the patient still has bronchorrhea (audible secretions, frothy ETT secretions, pulmonary crackles), atropine should continue. True atropine toxicity in OP poisoning is rare because the excess ACh competes with atropine at muscarinic receptors. I would reassess breath sounds and ETT secretions - if secretions are dry, I can reduce the atropine dose; if secretions persist, I will continue titration despite the tachycardia.

Q3 - The Succinylcholine Trap During RSI

"Your OP-poisoned patient is combative and needs immediate intubation. The anaesthesia resident reaches for succinylcholine. What do you do and why?"

Model Answer: I would stop the anaesthesia resident and explain that succinylcholine is metabolized by pseudocholinesterase (BuChE/plasma cholinesterase), which is INHIBITED by organophosphates. This will result in dramatically prolonged neuromuscular blockade - potentially 30 minutes to several hours - causing prolonged apnea without the ability to reverse. The safe alternative is rocuronium (1.2 mg/kg for RSI dose), which can be reversed with sugammadex if needed. This is a potentially fatal error if not corrected.

Q4 - Intermediate Syndrome Recognition

"Your OP-poisoned patient was improving on Day 1 after initial atropine treatment. On Day 2, the nursing staff calls you because the patient is developing progressive weakness and cannot hold their head up. Vitals: HR 90, BP 110/70, SpO2 93% on room air, no bronchorrhea. What is happening and what do you do?"

Model Answer: This is the Intermediate Syndrome (IMS) - occurring 24-96 hours after acute cholinergic crisis, characterized by proximal limb weakness, neck flexor weakness, cranial nerve palsies, and most critically - respiratory muscle weakness. It is NOT a recurrence of muscarinic toxicity (no bronchorrhea, no bradycardia). Atropine and oximes are INEFFECTIVE for IMS. This patient is heading toward respiratory failure: SpO2 93% is alarming. I would immediately assess respiratory muscle strength (NIF, FVC), prepare for elective intubation before decompensation, and initiate mechanical ventilation. This patient needs ICU admission for 2-3 weeks of ventilatory support. Recognize that IMS is the SECOND WAVE of mortality in OP poisoning.

Q5 - Seizures Not Responding to Phenytoin

"A nurse gives phenytoin to your seizing OP patient as per the hospital's standard seizure protocol. The seizures continue. Explain why and what you will do."

Model Answer: Phenytoin is a sodium channel blocker and is INEFFECTIVE for organophosphate seizures. OP-induced seizures are driven by excess ACh acting at NMDA receptors and cholinergic synapses - a GABAergic deficit combined with glutamatergic excess. Phenytoin does not address either of these mechanisms. First-line treatment is high-dose benzodiazepines (lorazepam 4mg IV, or diazepam 10mg IV, repeatable). If seizures are refractory, propofol infusion or midazolam infusion followed by barbiturate coma (phenobarbital or thiopental) are the escalation steps. Concurrent adequate atropinization must be ensured (reducing central ACh burden). Ketamine (NMDA antagonist) is emerging as adjunct therapy in refractory OP seizures.

Q6 - The Aging Concept and Oxime Timing

"A patient presents 36 hours after ingesting parathion, severely ill. The toxicology fellow wants to start pralidoxime. The attending says it's too late. Who is right and what determines the answer?"

Model Answer: Both have valid points. The answer depends on the specific organophosphate and the time to aging. Aging is the irreversible conformational change that permanently inactivates the OP-AChE complex; once aging occurs, oximes CANNOT regenerate AChE. The time to aging varies dramatically: soman ages in minutes, making oximes useless even if given quickly; parathion ages over hours to days - 36 hours may still be within the effective window for parathion. Additionally, even if significant aging has occurred, oximes may still have some benefit via their direct antimuscarinic and antinicotinic properties, or because a proportion of enzyme may not yet have aged. My recommendation: check if the compound is known, consult poison control for compound-specific aging data. In practice, if there is any reasonable likelihood the enzyme has not fully aged, give pralidoxime - the risk of giving it is low.

Q7 - OP vs Carbamate - The Treatment Dilemma

"A patient presents with classic cholinergic toxidrome. The product bottle says 'Sevin' (carbaryl - a carbamate). Should you give atropine? Should you give pralidoxime? Does the management differ?"

Model Answer: Atropine: YES - atropine is indicated regardless of whether this is an OP or carbamate, as both cause excess ACh at muscarinic sites and atropine is the antidote.

Pralidoxime: CONTROVERSIAL. Carbamates spontaneously dissociate from AChE (no aging), so the enzyme regenerates on its own within hours. Oximes are theoretically unnecessary. Moreover, some animal data suggests certain carbamates (particularly carbaryl/Sevin) may have WORSENED outcomes with 2-PAM. However, the Rosen's approach is: use oximes only if the poisoning is severe OR if the distinction between carbamate and OP cannot be reliably made. If the product label is known and confirmed as carbamate, I can withhold 2-PAM and rely on atropine + supportive care. The carbamate syndrome is generally shorter in duration (hours, not days).

Q8 - The Second Presentation - Lipid-Soluble OP

"A farmworker presents with mild symptoms of OP poisoning and improves spontaneously after decontamination. He wants to go home. On examination: slightly diaphoretic, pupils 2mm, HR 55. You let him go. 18 hours later, he returns in extremis with bronchorrhea and is crashing. What happened and what is your assessment of the first ED visit?"

Model Answer: This patient was poisoned by a fat-soluble organophosphate (e.g., fenthion, chlorpyrifos). These compounds are absorbed and initially sequestered in adipose tissue, causing mild early symptoms. As the fat stores release the compound over hours, delayed systemic toxicity develops, sometimes 12-72 hours after apparent initial recovery. This is also called "depot effect" toxicity. The management error at the first visit was premature discharge. Any symptomatic OP patient - even mildly symptomatic - with abnormal vitals or small pupils should be admitted for a minimum 24-48 hour observation. Serial cholinesterase levels (falling trend indicates ongoing absorption) and knowledge of the compound's lipid solubility are key to safe disposition.

Q9 - QT Prolongation and Cardiac Death

"An intubated OP patient on the ventilator suddenly develops a wide-complex tachycardia on Day 3. His rhythm appears to be torsades de pointes. How do you manage this and what are the contributing factors in OP poisoning?"

Model Answer: Torsades de pointes (TdP) in OP poisoning is multifactorial:

Direct OP cardiotoxicity with QTc prolongation
Electrolyte abnormalities from GI losses (hypokalemia, hypomagnesemia)
Autonomic dysregulation (parasympathetic predominance causing bradycardia)
Some OPs have direct sodium channel blocking effect

Management of TdP:

Immediate IV magnesium sulfate 2g over 2-3 minutes - first-line
Correct hypokalemia (target K+ > 4.0 mEq/L)
Consider overdrive pacing (transcutaneous/transvenous) to shorten QT
If atropine is still needed for bronchorrhea, it may help by increasing heart rate (shortening QTc)
Review all QT-prolonging medications
If degeneration to VF: standard ACLS, defibrillation

Q10 - The Ethical/Practical Mass Casualty Scenario

"A chemical attack with a nerve agent affects 50 people simultaneously in a concert hall. Twenty arrive to your ED within 15 minutes, all with varying degrees of cholinergic toxidrome. Your hospital stocks 100mg of atropine total. What do you do?"

Model Answer: This is a mass casualty incident (MCI) with chemical exposure. My immediate actions:

Activate MCI protocol immediately; notify hospital incident command, call poison control
Decontamination corridor established OUTSIDE the ED; all patients decontaminated before entering - this is non-negotiable to prevent secondary contamination of staff and facility
Triage: Use START or modified triage; prioritize those with bronchorrhea/respiratory distress. The "immediate" category gets atropine first.
Atropine conservation: With limited stock, use auto-injectors (DuoDote - atropine 2.1mg + pralidoxime 600mg) if available from CHEMPACK or emergency stockpile. Contact state/national emergency pharmaceutical stockpile immediately.
Pralidoxime from the DuoDote kits can extend atropine effect by preventing further AChE inhibition
Glycopyrrolate can be used as an atropine substitute if supply is critical
Notify regional poison center and neighboring hospitals to share antidote burden and reroute patients
Deaths in MCI from OP occur from respiratory failure - prioritize securing airways, even with surgical airway if needed
Consider sublingual atropine (research-stage but viable in desperation)
Document all doses given carefully; once secretions are controlled, use atropine infusion to conserve remaining stock

KEY SOURCES

Rosen's Emergency Medicine: Concepts and Clinical Practice, 10e, Chapter 152 (Pesticides)
Tintinalli's Emergency Medicine: A Comprehensive Study Guide, 9e, Chapter on Organophosphates
Katzung's Basic and Clinical Pharmacology, 16e (Cholinesterase Inhibitors)
Bradley & Daroff's Neurology in Clinical Practice (OPIDN and Intermediate Syndrome)
Chauhan V et al. "Therapeutic Interventions in Organophosphate Poisoning: An Umbrella Review of Systematic Reviews." West J Emerg Med. 2026. PMID 42258859 - most current evidence synthesis
Rashid M et al. "Efficacy and Safety of Glycopyrrolate in the Management of OPC Poisoning: A Systematic Review." Curr Rev Clin Exp Pharmacol. 2025. PMID 38797902

This is a shared conversation. Sign in to Orris to start your own chat.